Pharma & Biotech - Page 20

Quanterix Corporation has appointed medtech veteran Jim Gute as its new chief commercial officer, signalling an ambitious push to accelerate commercial growth. Gute joins Quanterix from Exact Sciences, where he served as

Scholar Rock has removed Novo Nordisk’s Catalent manufacturing facility from its FDA submission for apitegromab, a spinal muscular atrophy treatment candidate, following a damaging inspection outcome. The troubled plant received an “Official

BridgeBio Pharma’s Attruby generated net product revenue of $222.4 million in Q2 2026, more than tripling the $71.5 million recorded in the same period a year ago. Total revenues climbed 120% to

WuXi AppTec has secured an early legal victory in its fight against the US Department of Defense over its controversial designation as a “Chinese military company.” Chief Judge James E. Boasberg of

Launched earlier this year, TrumpRx is a White House initiative designed to give patients access to drugs priced in line with what other developed nations pay. The administration has branded this approach

ITM Isotope Technologies Munich SE has received a Complete Response Letter from the U.S. Food and Drug Administration, blocking approval of its cancer drug ITM-11. The FDA issued the CRL on August

Abbott Laboratories (ABT) has signed telenovela star Gabriela Spanic to front a Spanish-language campaign promoting colorectal cancer screening among Hispanic adults in the United States. Spanic rose to international fame through the

President Donald Trump signed an executive order on August 10, 2026, titled “Delivering Gold Standard Childhood Vaccine Recommendations for Americans,” narrowing the recommended childhood vaccine list. The order reduces the number of

The prolonged Strait of Hormuz standoff is deepening concerns across pharmaceutical supply chains, with no resolution appearing imminent from either side. President Trump has signalled the US is prepared to let economic

Tenax Therapeutics (Nasdaq: TENX) has announced that its Phase 3 LEVEL clinical trial evaluating TNX-103, an oral form of levosimendan, failed to meet its primary endpoint. The trial, which enrolled 241 patients